Pfizer: positive study data in prostate cancer

(CercleFinance.com) - Pfizer announces positive top-line results for the final pre-specified analysis of overall survival in the TALAPRO-2 study of Talzenna in combination with Xtandi in patients with metastatic castration-resistant prostate cancer.


According to the pharmaceutical company, these results showed a statistically and clinically significant improvement in final overall survival in all participants, regardless of mutation status, compared to Xtandi alone.

Detailed results from TALAPRO-2 will be presented at an upcoming medical congress, and shared with global health authorities to support regulatory filings to update and potentially expand Talzenna's approved label.


Copyright (c) 2024 CercleFinance.com. All rights reserved.